ClinicalTrials.gg
RecruitingNCT06079541Updated Oct 17, 2023

Phase 1 Clinical Study of JMKX003142 Tablets

A Phase 1 interventional study of JMKX003142 will be administered orally and JMKX003142 will be administered orally in Safety and Tolerability, sponsored by Jemincare. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-17.

Sponsored by Jemincare · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 3 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled Jul 2023, registered Oct 2023).
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of JMKX003142 tablets administered randomly, double-blind, placebo-controlled single and multiple times in healthy adult subjects, as well as the effects of randomized, open, and two cycle crossover foods

02

Conditions studied

  • Safety and Tolerability
03

In context

Lead sponsor

Jemincare is the lead sponsor of 37 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female subjects aged 18-45 years (including boundary values)
  2. Able to sign a written form
  3. Physical examination, clinical laboratory examination value, Virology examination, vital signs and 12 lead examination are confirmed by the researcher to be normal or abnormal without clinical significance
  4. The subjects have a thorough understanding of the study content, process, and potential adverse effects, and are willing to complete the study according to the requirements of the experimental protocol

Exclusion criteria

Exclusion Criteria:

  1. Had or currently have serious clinical diseases related to circulatory system, respiratory system, digestive system, nervous system, endocrine system, blood lymphatic system, genitourinary system or psychiatry, as well as habitual constipation, gastrointestinal bleeding history, which is judged to be inappropriate for the study by the investigators
  2. Participants in any other clinical study within 3 months prior to the first administration of this study
  3. The investigators believe that the subject has other factors that are not suitable for participating in this experiment
  4. Pregnant or lactating women
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
106 participants (estimated)

Study arms

  • Experimental
    JMKX003142 SAD experimental group

    Participants will be randomized into 7 cohorts to receive single oral dose of JMKX003142 on Day 1. The doses in each cohort will be escalated based on the safety and pharmacokinetics (PK) / Pharmacodynamics (PD) data of the previous cohort.

    Drug: JMKX003142 will be administered orally

  • Experimental
    JMKX003142 MAD experimental group

    Participants will be randomized into 3 cohorts to receive orally once -daily of JMKX003142 for 7 consecutive days. The second cohort will be escalated based on the safety and pharmacokinetics (PK)/ Pharmacodynamics (PD) data of the previous cohort.

    Drug: JMKX003142 will be administered orally

  • Experimental
    JMKX003142 FE experimental group

    Participants will receive 2 Sequence regimens, with a washout period between treatments.

    Drug: JMKX003142 will be administered orally

  • Experimental
    Placebo in Cohorts 1 to 7

    Participants in Cohorts 1 to 7 will receive single oral dose of matching placebo on Day 1.

    Drug: Placebo in Cohorts 1 to 7

  • Experimental
    Placebo in 3 Cohorts

    Participants in 3 Cohorts will receive orally once -daily of matching placebo for 7 consecutive days.

    Drug: Placebo in 3 Cohorts

Interventions

06

What researchers measure

Primary outcomes

  1. Number of the Adverse Events that are related to the single dose treatment

    single dose safety

    Time frame: from baseline to Day 18

  2. Number of the Adverse Events that are related to the multiple dose treatment from

    multiple dose safety

    Time frame: from baseline to Day 24

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for Jul 2024, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2023
First posted
Oct 12, 2023
StartActual
Jul 6, 2023
Primary completionEst.
Jul 31, 2024
CompletionEst.
Mar 30, 2025
Last update
Oct 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06079541
Lead sponsor
Jemincare
Collaborators
Zhejiang Hangyu Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Oct 12, 2023
Start date
Jul 6, 2023
Primary completion
Jul 31, 2024 (estimated)
Completion
Mar 30, 2025 (estimated)
Last update
Oct 17, 2023

Study contacts

jianping Su
Contact
sujianping@jemincare.com
+86 15162481262
Xuening li
principal investigator · Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JMKX003142

Start the discussion